Antibiotice Ia (RO:ATB) — Market Cap & Net Worth
Market Cap & Net Worth: Antibiotice Ia (ATB)
Antibiotice Ia (RO:ATB) has a market capitalization of $315.24 Million (RON1.37 Billion) as of August 27, 2026. Listed on the RO stock exchange, this Romania-based company holds position #14733 globally and #22 in its home market, demonstrating a -2.62% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Antibiotice Ia's stock price RON2.05 by its total outstanding shares 671338040 (671.34 Million). Check Antibiotice Ia (ATB) share price today for real-time trading data and today's change.
Antibiotice Ia Market Cap History: 2015 to 2026
Antibiotice Ia's market capitalization history from 2015 to 2026. Data shows growth from $61.66 Million to $315.24 Million (15.66% CAGR).
Index Memberships
Antibiotice Ia is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
Bucharest Plus Index
BETPLUS
|
$70.53 Billion | 0.45% | #14 of 42 |
Weight: Antibiotice Ia's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Antibiotice Ia Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Antibiotice Ia's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check ATB net assets to evaluate the company's book value and shareholders' equity.
Latest Price to Sales (P/S) Ratio
0.59x
Antibiotice Ia's market cap is 0.59 times its annual revenue
Latest Price to Earnings (P/E) Ratio
7.30x
Antibiotice Ia's market cap is 7.30 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2020 | $71.42 Million | $340.42 Million | $26.39 Million | 0.21x | 2.71x |
| 2021 | $89.58 Million | $366.21 Million | $29.94 Million | 0.24x | 2.99x |
| 2022 | $84.18 Million | $483.72 Million | $51.47 Million | 0.17x | 1.64x |
| 2023 | $209.37 Million | $600.78 Million | $81.09 Million | 0.35x | 2.58x |
| 2024 | $394.62 Million | $675.01 Million | $102.20 Million | 0.58x | 3.86x |
| 2025 | $377.67 Million | $645.28 Million | $51.77 Million | 0.59x | 7.30x |
Competitor Companies of ATB by Market Capitalization
Companies near Antibiotice Ia in the global market cap rankings as of August 27, 2026. Also see cash flow conversion of Antibiotice Ia for how efficiently the company converts equity into cash flow.
Key companies related to Antibiotice Ia by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #520 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #558 globally with a market cap of $49.37 Billion USD.
- Haleon plc (NYSE:HLN): Ranked #633 globally with a market cap of $43.73 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #635 globally with a market cap of $43.63 Billion USD ( CN¥298.15 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #520 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #558 | GALDERMA GROUP AG | NYSE:GALDY | $49.37 Billion | $42.34 |
| #633 | Haleon plc | NYSE:HLN | $43.73 Billion | $10.17 |
| #635 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $43.63 Billion | CN¥46.74 |
Antibiotice Ia Historical Marketcap From 2015 to 2026
Between 2015 and today, Antibiotice Ia's market cap moved from $61.66 Million to $ 315.24 Million, with a yearly change of 15.66%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | RON315.24 Million | -16.53% |
| 2025 | RON377.67 Million | -4.30% |
| 2024 | RON394.62 Million | +88.48% |
| 2023 | RON209.37 Million | +148.71% |
| 2022 | RON84.18 Million | -6.02% |
| 2021 | RON89.58 Million | +25.43% |
| 2020 | RON71.42 Million | +1.18% |
| 2019 | RON70.59 Million | +6.36% |
| 2018 | RON66.36 Million | -4.46% |
| 2017 | RON69.46 Million | +10.74% |
| 2016 | RON62.72 Million | +1.73% |
| 2015 | RON61.66 Million | -- |
End of Day Market Cap According to Different Sources
On Aug 27th, 2026 the market cap of Antibiotice Ia was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $315.24 Million USD |
| MoneyControl | $315.24 Million USD |
| MarketWatch | $315.24 Million USD |
| marketcap.company | $315.24 Million USD |
| Reuters | $315.24 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Antibiotice Ia
Antibiotice S.A. produces and sells medicinal products in Romania and internationally. The company provides generic prescription medicines comprising anti-infectives, including drugs for the treatment of tuberculosis, as well as cardiovascular drugs, digestive tract and metabolism class, preparations for the treatment of gynecological diseases, and dermatological and central nervous system prepar… Read more